NR565-
,/. Advanced,/.Pharm_week,/.6,/.study,/.guide,/.for,/.final
1. Which,/.of,/.the,/.following,/.best,/.describes,/.asthma?:,/.A,/.chronic,/.inflammatory,/.airway,/.disor
der,/.with,/.reversible,/.airflow,/.obstruction
2. Which,/.of,/.the,/.following,/.is,/.most,/.likely,/.to,/.trigger,/.an,/.asthma,/.attack?:,/.Exercis
e,/.or,/.respiratory,/.infection
3. What,/.is,/.the,/.underlying,/.pathological,/.process,/.in,/.asthma?:,/.Inflammation,/.leading,/.
to,/.airway,/.hyperresponsiveness
4. Which,/.of,/.the,/.following,/.symptoms,/.is,/.most,/.characteristic,/.of,/.asthma?:,/.Ch
est,/.tightness,/.and,/.wheezing,,/.especially,/.at,/.night
5. What,/.is,/.the,/.mechanism,/.of,/.action,/.of,/.ipratropium,/.in,/.the,/.treatment,/.of,/.ast
hma,/.or,/.COPD?:,/.Inhibits,/.muscarinic,/.receptors,/.to,/.prevent,/.bronchoconstriction
6. Ipratropium,/.is,/.primarily,/.classified,/.as,/.which,/.of,/.the,/.following?:,/.Short-
acting,/.mus-
carinic,/.antagonist,/.(SAMA)
7. Which,/.of,/.the,/.following,/.is,/.a,/.common,/.side,/.effect,/.associated,/.with,/.inhale
d,/.ipratropium,/.use?:,/.Dry,/.mouth
8. In,/.which,/.patient,/.population,/.is,/.ipratropium,/.most,/.commonly,/.used,/.as,/.first-
line,/.therapy?:,/.Patients,/.with,/.COPD
9. Ipratropium,/.may,/.be,/.used,/.as,/.adjunctive,/.therapy,/.in,/.asthma,/.primarily,/.to::,/.Provi
de
additional, / . bronchodilation, / . when, / . beta-agonists, / . alone, / . are, / . insuflcient
10. Omalizumab,/.is,/. classified,/. as,/. which,/. type,/.of,/. medication?:,/. Monoclonal,/.antibody
11. What,/.is,/.the,/.primary,/.mechanism,/.of,/.action,/.of,/.omalizumab,/.in,/.asthma,/.tr
eat-ment?:,/.Binds,/.to,/.IgE,/.to,/.prevent,/.mast,/.cell,/.activation
12. Omalizumab,/.is,/.most,/.appropriate,/.for,/.which,/.type,/.of,/.asthma,/.patient?:,/.A,/.pa
tient
with,/.moderate,/.to,/.severe,/.allergic,/.asthma,/.not,/.controlled,/.by,/.ICS
13. What,/.is,/.a,/.serious,/.adverse,/.effect,/.associated,/.with,/.omalizumab,/.that,/.requir
es,/.post-
injection,/.monitoring,/.that,/.requires,/.it,/.to,/.have,/.a,/.black,/.box,/.warning?:,/.Anaphy-
laxis
14. How, / . is, / . omalizumab, / . typically, / . administered?:, / . Subcutaneously,/.or,/.intravenously
15. What,/.is,/.the,/.primary,/.mechanism,/.of,/.action,/.of,/.bronchodilators,/.in,/.the,/.treat
,/. ,/.
, NR565-
,/.Advanced,/.Pharm_week,/.6,/.study,/.guide,/.for,/.final
-
ment,/.of,/.asthma,/.and,/.COPD?:,/.Relaxing,/.bronchial,/.smooth,/.muscle,/.to,/.relieve,/.airway,/.obstruction
16. Which,/.of,/.the,/.following,/.is,/.considered,/.a,/.short-acting,/.beta-
2,/.agonist,/.(SABA)?-
:,/.Albuterol
,/. ,/.
,/. Advanced,/.Pharm_week,/.6,/.study,/.guide,/.for,/.final
1. Which,/.of,/.the,/.following,/.best,/.describes,/.asthma?:,/.A,/.chronic,/.inflammatory,/.airway,/.disor
der,/.with,/.reversible,/.airflow,/.obstruction
2. Which,/.of,/.the,/.following,/.is,/.most,/.likely,/.to,/.trigger,/.an,/.asthma,/.attack?:,/.Exercis
e,/.or,/.respiratory,/.infection
3. What,/.is,/.the,/.underlying,/.pathological,/.process,/.in,/.asthma?:,/.Inflammation,/.leading,/.
to,/.airway,/.hyperresponsiveness
4. Which,/.of,/.the,/.following,/.symptoms,/.is,/.most,/.characteristic,/.of,/.asthma?:,/.Ch
est,/.tightness,/.and,/.wheezing,,/.especially,/.at,/.night
5. What,/.is,/.the,/.mechanism,/.of,/.action,/.of,/.ipratropium,/.in,/.the,/.treatment,/.of,/.ast
hma,/.or,/.COPD?:,/.Inhibits,/.muscarinic,/.receptors,/.to,/.prevent,/.bronchoconstriction
6. Ipratropium,/.is,/.primarily,/.classified,/.as,/.which,/.of,/.the,/.following?:,/.Short-
acting,/.mus-
carinic,/.antagonist,/.(SAMA)
7. Which,/.of,/.the,/.following,/.is,/.a,/.common,/.side,/.effect,/.associated,/.with,/.inhale
d,/.ipratropium,/.use?:,/.Dry,/.mouth
8. In,/.which,/.patient,/.population,/.is,/.ipratropium,/.most,/.commonly,/.used,/.as,/.first-
line,/.therapy?:,/.Patients,/.with,/.COPD
9. Ipratropium,/.may,/.be,/.used,/.as,/.adjunctive,/.therapy,/.in,/.asthma,/.primarily,/.to::,/.Provi
de
additional, / . bronchodilation, / . when, / . beta-agonists, / . alone, / . are, / . insuflcient
10. Omalizumab,/.is,/. classified,/. as,/. which,/. type,/.of,/. medication?:,/. Monoclonal,/.antibody
11. What,/.is,/.the,/.primary,/.mechanism,/.of,/.action,/.of,/.omalizumab,/.in,/.asthma,/.tr
eat-ment?:,/.Binds,/.to,/.IgE,/.to,/.prevent,/.mast,/.cell,/.activation
12. Omalizumab,/.is,/.most,/.appropriate,/.for,/.which,/.type,/.of,/.asthma,/.patient?:,/.A,/.pa
tient
with,/.moderate,/.to,/.severe,/.allergic,/.asthma,/.not,/.controlled,/.by,/.ICS
13. What,/.is,/.a,/.serious,/.adverse,/.effect,/.associated,/.with,/.omalizumab,/.that,/.requir
es,/.post-
injection,/.monitoring,/.that,/.requires,/.it,/.to,/.have,/.a,/.black,/.box,/.warning?:,/.Anaphy-
laxis
14. How, / . is, / . omalizumab, / . typically, / . administered?:, / . Subcutaneously,/.or,/.intravenously
15. What,/.is,/.the,/.primary,/.mechanism,/.of,/.action,/.of,/.bronchodilators,/.in,/.the,/.treat
,/. ,/.
, NR565-
,/.Advanced,/.Pharm_week,/.6,/.study,/.guide,/.for,/.final
-
ment,/.of,/.asthma,/.and,/.COPD?:,/.Relaxing,/.bronchial,/.smooth,/.muscle,/.to,/.relieve,/.airway,/.obstruction
16. Which,/.of,/.the,/.following,/.is,/.considered,/.a,/.short-acting,/.beta-
2,/.agonist,/.(SABA)?-
:,/.Albuterol
,/. ,/.
